North America Point-of-Care Molecular Testing for Infectious
Diseases Market Share, Trends, Size, Segmentation And Forecast To 2031

Infectious disease management is increasingly
focusing on the principle of early and accurate diagnosis as a cornerstone of
disease control and prevention. Rapid molecular testing plays an essential role
in identifying cases during the early stages of infection, allowing for prompt
intervention and isolation measures when necessary. In outbreak scenarios,
point-of-care diagnostics contribute significantly to the containment and
surveillance efforts by providing real-time epidemiological insights. This
capability is especially relevant in community settings, where traditional
laboratory infrastructure may not be readily available.

The global North America point-of-care molecular testing for
infectious diseases market is expected to reach US$ 44.59 billion in 2031 from
US$ 19.21 billion in 2023. The market is estimated to grow with a CAGR of 11.1%
from 2023 to 2031.

The North America Point-of-Care Molecular Testing for
Infectious Diseases Market is witnessing significant growth, driven by rising
incidences of infectious diseases, increasing demand for rapid diagnostic
results, and technological advancements in molecular diagnostics. This market
segment is reshaping how healthcare systems manage and respond to infectious
threats, particularly in decentralized settings such as clinics, pharmacies,
and even homes. The North America Point-of-Care Molecular Testing for
Infectious Diseases Market is benefitting from a growing focus on early
detection and timely treatment, which can significantly improve patient
outcomes and curb disease transmission.

https://www.businessmarketinsights.com/reports/north-america-point-of-care-molecular-testing-for-infectious-diseases-market

The COVID-19 pandemic served as a major catalyst for the North
America Point-of-Care Molecular Testing for Infectious Diseases Market,
emphasizing the need for scalable, accurate, and quick diagnostic tools.
Point-of-care molecular testing gained traction as healthcare providers sought
solutions that offered laboratory-level precision without requiring centralized
lab infrastructure. The convenience of these systems has helped the North
America Point-of-Care Molecular Testing for Infectious Diseases Market expand
rapidly, especially in underserved or remote areas where access to traditional
labs is limited.

Innovations such as cartridge-based nucleic acid
amplification tests (NAATs), real-time PCR systems, and isothermal
amplification technologies are central to the North America Point-of-Care
Molecular Testing for Infectious Diseases Market. These solutions enable
clinicians to detect pathogens like influenza, RSV, HIV, COVID-19, and
streptococcus within minutes. The speed and accuracy of these tests are fueling
widespread adoption across hospitals, urgent care centers, and mobile
healthcare units, propelling the growth of the North America Point-of-Care
Molecular Testing for Infectious Diseases Market.

Another factor supporting the rise of the North America
Point-of-Care Molecular Testing for Infectious Diseases Market is the shift
toward personalized medicine and value-based care. Rapid diagnostics reduce the
need for presumptive treatments and hospital admissions, leading to cost
savings for both providers and patients. Moreover, regulatory bodies in North
America are streamlining the approval process for innovative diagnostics,
accelerating the commercialization of new technologies in the North America
Point-of-Care Molecular Testing for Infectious Diseases Market.

The versatility of point-of-care molecular platforms makes
them a vital tool in outbreak management. Whether in emergency rooms, long-term
care facilities, or border checkpoints, these systems play a critical role in
preventing the spread of infections. This dynamic is expected to further
elevate the North America Point-of-Care Molecular Testing for Infectious
Diseases Market in the coming years, particularly as emerging pathogens pose
ongoing public health challenges.

With an increasing emphasis on real-time surveillance and
global health security, stakeholders are investing heavily in the North America
Point-of-Care Molecular Testing for Infectious Diseases Market. Public-private
partnerships, strategic collaborations, and robust R\&D initiatives are
shaping the competitive landscape. As awareness continues to grow among
clinicians and consumers alike, the North America Point-of-Care Molecular
Testing for Infectious Diseases Market is poised to become a cornerstone of
modern infectious disease management, delivering efficient, decentralized
diagnostics that meet the evolving demands of today’s healthcare ecosystem.

The
List Of Companies.

Abbott Laboratories

Agilent Technologies Inc

Becton Dickinson and Co

Bio-Rad Laboratories Inc

Cardinal Health Inc,

Danaher Corp

Cue Health Inc,

QuidelOrtho Corp

Thermo Fisher Scientific Inc

F. Hoffmann-La Roche Ltd.

The North America point-of-care molecular testing for
infectious diseases market forecast presented in this report can help
stakeholders in this marketplace plan their growth strategies. The surging
prevalence of infectious diseases and preference for rapid diagnostic solutions
are the key factors propelling the market development. However, inadequate
reimbursement scenarios impede the North America point-of-care molecular
testing for infectious diseases market growth.

Market Opportunities
of North America Point-Of-Care Molecular Testing For Infectious Diseases Market

Research and development (R&D) is an essential component
of pharmaceutical and biopharmaceutical companies. R&D enables market
players to develop new products for various therapeutic applications with
significant medical and commercial potential. The following table displays the
annual funding for various research and disease categories based on contracts,
grants, and other funding mechanisms adopted by the NIH.

North America
Point-Of-Care Molecular Testing for Infectious Diseases Market: Regional
Overview

The increasing prevalence of infectious diseases, the rising
geriatric population, and a surging number of product launches by key players
are the primary contributors to the point-of-care testing for infectious
diseases market growth in the US. Aging is a prominent risk factor for
infectious diseases, as people aged more than 60 may have compromised immunity.
According to a study published by the Population Reference Bureau in 2020, the
population of individuals aged 65 and above was 55 million in the US in 2020,
and the number is expected to reach 95 million by 2060. Regulatory agencies in
the US rigorously monitor the development of point-of-care (POC) testing
products. For instance, in March 2021, the US Food Drug Administration (FDA)
authorized Binx Health IO CT/NG Assay for community-based clinics, urgent care
settings, and outpatient healthcare facilities; it is the first POC testing
product for diagnosing chlamydial and gonorrheal infections.

A few of the major primary and secondary sources referred to
while preparing the report on the North America point-of-care molecular testing
for infectious diseases market are the World Bank Data, National Health Service
(NHS), US Department of Health and Human Services (HHS), and WHO (World Health
Organization).

North America
Point-of-Care Molecular Testing for Infectious Diseases Strategic Insights

Strategic insights for the North America Point-of-Care
Molecular Testing for Infectious Diseases provides data-driven analysis of the
industry landscape, including current trends, key players, and regional
nuances. These insights offer actionable recommendations, enabling readers to
differentiate themselves from competitors by identifying untapped segments or
developing unique value propositions. Leveraging data analytics, these insights
help industry players anticipate the market shifts, whether investors,
manufacturers, or other stakeholders. A future-oriented perspective is
essential, helping stakeholders anticipate market shifts and position
themselves for long-term success in this dynamic region. Ultimately, effective
strategic insights empower readers to make informed decisions that drive
profitability and achieve their business objectives within the market.

About Us-

Business
Market Insights is a market research platform that provides subscription
service for industry and company reports. Our research team has extensive
professional expertise in domains such as Electronics & Semiconductor;
Aerospace & Defense; Automotive & Transportation; Energy & Power;
Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals
& Materials; and Technology, Media, & Telecommunications.